These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23676589)

  • 1. Maintenance of the remission stage of Crohn's disease with adalimumab therapy during pregnancy.
    Mizoshita T; Tanida S; Tsukamoto H; Ozeki K; Katano T; Ebi M; Mori Y; Kataoka H; Kamiya T; Joh T
    Intern Med; 2013; 52(10):1049-53. PubMed ID: 23676589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis induced clinical remission in a Crohn's disease patient with the loss of response to scheduled adalimumab maintenance therapy: a case report.
    Ozeki K; Tanida S; Mizushima T; Mizoshita T; Tsukamoto H; Hirata Y; Murakami K; Shimura T; Kataoka H; Kamiya T; Joh T
    Intern Med; 2012; 51(6):595-9. PubMed ID: 22449667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crohn's Disease in which the Patient Developed Aortitis during Treatment with Adalimumab.
    Kiyohara H; Hisamatsu T; Matsuoka K; Naganuma M; Kameda H; Seta N; Takeuchi T; Kanai T
    Intern Med; 2015; 54(14):1725-32. PubMed ID: 26179525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
    Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
    J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.
    Tsuboi R; Matsumoto S; Miyatani H; Mashima H
    Intern Med; 2019 Mar; 58(5):649-654. PubMed ID: 30333413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case report: feasible treatment of adalimumab for Crohn disease during pregnancy].
    Tsujikawa T; Sakai S; Fujii M; Saotome T; Imaeda H; Bamba S; Andoh A; Fujiyama Y
    Nihon Shokakibyo Gakkai Zasshi; 2013 Feb; 110(2):243-7. PubMed ID: 23381212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn's disease patients.
    Ishida K; Inoue T; Fujiwara K; Sakanaka T; Narabayashi K; Nouda S; Okada T; Kakimoto K; Kuramoto T; Kawakami K; Abe Y; Takeuchi T; Murano M; Tokioka S; Umegaki E; Higuchi K
    World J Gastroenterol; 2013 May; 19(17):2676-82. PubMed ID: 23674875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
    Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
    J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy.
    Mishkin DS; Van Deinse W; Becker JM; Farraye FA
    Inflamm Bowel Dis; 2006 Aug; 12(8):827-8. PubMed ID: 16917239
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab induces deep remission in patients with Crohn's disease.
    Colombel JF; Rutgeerts PJ; Sandborn WJ; Yang M; Camez A; Pollack PF; Thakkar RB; Robinson AM; Chen N; Mulani PM; Chao J
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):414-22.e5. PubMed ID: 23856361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.